10:25 AM
 | 
Nov 30, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

On heels of Sobi deal, Novimmune's emapalumab gets FDA approval

FDA approved Gamifant emapalumab-lzsg from Novimmune S.A. (Plan-les-Ouates, Switzerland), giving Novimmune a Priority Review voucher and the first U.S.-approved drug for hemophagocytic lymphohistiocytosis (HLH). Novimmune said it plans to sell the Priority Review voucher. The approval comes just four months after Swedish Orphan Biovitrum AB (SSE:SOBI) gained exclusive, worldwide rights to Gamifant in a deal which stipulated that Sobi cover all development and commercialization costs beginning in September.

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >